Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ABL2
REST API REST API
Homo sapiens
ABL2 is differentially expressed in 267 experiments: 122 organism parts: bone marrow, hypothalamus, ... (120 more);, 184 disease states: normal, breast carcinoma, ... (182 more);, 81 cell types 361 cell lines 38 compound treatments and 73 other conditions.
Synonyms ARG, ABLL
Orthologs ABL2 (Bos taurus)   ENSCING00000003255 (Ciona intestinalis)   abl2 (Danio rerio)   Abl2 (Mus musculus)   ABL2 (Gallus gallus)   Abl (Drosophila melanogaster)   abl2 (Xenopus laevis)   ABL2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, regulation of cell adhesion, protein binding, actin monomer binding, cytoplasm, actin filament bundle assembly, peptidyl-tyrosine phosphorylation, protein tyrosine kinase activity, actin filament organization, regulation of autophagy, ATP binding, magnesium ion binding, axon guidance, actin cytoskeleton, transferase activity, transferring phosphorus-containing groups, protein modification process, manganese ion binding, nucleotide binding, protein serine/threonine kinase activity, actin filament binding, non-membrane spanning protein tyrosine kinase activity, signal transduction, protein kinase activity, cellular response to retinoic acid, positive regulation of neuron projection development, regulation of endocytosis, positive regulation of oxidoreductase activity, protein phosphorylation, regulation of cell motility, regulation of actin cytoskeleton reorganization
InterPro Term SH2, SH3_domain, F-actin_binding, Prot_kinase_cat_dom, SH3_2, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom, SH3_3
UniProt Accession P42684, D1MPS6, F8WAF7
Search EB-eye ENSG00000143322
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MTAB-24, E-MTAB-25, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-GEOD-4717, ... (34 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF7
2
E-MTAB-37, E-GEOD-5258
WI38
2
E-MTAB-37, E-MTAB-62
PC3
1
2
E-MEXP-2034, E-GEOD-14464, E-GEOD-5258
BT474
1
2
E-MTAB-37, E-MTAB-62, E-MEXP-440
355 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-120, E-GEOD-360, ... (47 experiments)

Factor Value U/D Experiments
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
CD4+ T cell
2
E-MTAB-24, E-MTAB-25
1
2
E-TABM-145, E-TABM-130
macrophage
1
2
E-GEOD-5099, E-GEOD-22373, E-GEOD-360
CD105+ endothelial
1
1
E-TABM-145
fibroblast
1
E-GEOD-3920
75 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-16363, ... (55 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-MTAB-62
breast carcinoma
1
3
E-GEOD-5823, E-MTAB-37, E-GEOD-7307, E-TABM-276
chronic lymphocytic leukemia
2
E-GEOD-2466, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-MTAB-37
control
2
E-GEOD-21912, E-GEOD-16363
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
178 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (25 experiments)

Factor Value U/D Experiments
none
5
6
E-TABM-782, E-MEXP-1958, E-GEOD-5099, E-GEOD-1740, E-MEXP-1230, ... (11 experiments)
PGE2
1
E-MEXP-1230
control - keratinocyte growth factor
1
E-GEOD-7216
unknown
1
E-GEOD-7307
vanadium pentoxide
1
E-GEOD-5339
granulocyte macrophage-colony stimulating factor
1
E-GEOD-2803
32 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, E-MEXP-2283, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-MEXP-421, E-TABM-321, E-TABM-868, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-MEXP-2657, E-TABM-127, E-GEOD-20540, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (25 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-980, E-GEOD-6802

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-17636, E-MEXP-1403

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.481 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM